Chiasma to Report First Quarter Financial Results on May 6, 2021

Rhea-AI Summary

Chiasma, Inc. (NASDAQ: CHMA) will hold a live conference call and audio webcast on May 6, 2021, at 5:00 PM ET to discuss its financial results for Q1 2021 and provide a business update. The call can be accessed domestically at 800-909-4761 and internationally at 312-281-2942, with Conference ID 21993564. An archived replay of the call will be available on Chiasma's website. The company focuses on developing oral therapies for patients with chronic diseases, having received FDA approval for MYCAPSSA, the first oral somatostatin analog, in June 2020.

Positive

• FDA approval of MYCAPSSA, the first oral somatostatin analog, enhances market position.
• Development of oral therapies may expand treatment options for patients with chronic diseases.

Negative

• None.

NEEDHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter ended March 31, 2021 and to provide a business update.

Conference Call Details:

Thursday May 6, 2021, 5:00 PM ET

Domestic:	800-909-4761
International:	312-281-2942
Conference ID:	21993564
Webcast:	http://public.viavid.com/index.php?id=144460

A live audio webcast of the call may also be accessed under "Events & Presentations" on the News & Investors section of the Company's website, https://ir.chiasma.com/events-presentations. An archived replay of the webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.

About Chiasma
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.

Investor Relations and Corporate Communications:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com

FAQ

When will Chiasma discuss its Q1 2021 financial results?

Chiasma will discuss its Q1 2021 financial results on May 6, 2021, at 5:00 PM ET.

How can I access Chiasma's conference call?

You can access Chiasma's conference call domestically at 800-909-4761 and internationally at 312-281-2942, using Conference ID 21993564.

What significant product has Chiasma received FDA approval for?

Chiasma received FDA approval for MYCAPSSA, the first oral somatostatin analog, in June 2020.

Where can I find the archived replay of Chiasma's conference call?

The archived replay of Chiasma's conference call will be available on the company's website approximately two hours after the event.